Search
Isoflurophate
go.drugbank.com/drugs/DB00677ApprovedWithdrawnIts vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma.
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled penAmylmetacresol
go.drugbank.com/drugs/DB13908ApprovedAmylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections [L2570], [L2571]. … The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting.
Synonyms: 6-n-amyl-m-cresol, 6-n-pentyl-m-cresolFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalIn contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawncholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … difficulties and commercial infeasibility in continuing drug distribution.
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]